A-796,260
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.233.198 |
Chemical and physical data | |
Formula | C22H30N2O2 |
Molar mass | 354.485 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant selectivity for CB2, and A-796,260 was found to be a highly selective CB2 agonist with little affinity for CB1, having a CB2 Ki of 4.6 nM vs 945 nM at CB1.[1] It has potent analgesic and anti-inflammatory actions in animal models, being especially effective in models of neuropathic pain, but without producing cannabis-like behavioral effects.[2]
See also
References
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1021/jm901214q, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1021/jm901214q
instead. - ^ Yao BB; et al. (January 2008). "In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models". British Journal of Pharmacology. 153 (2): 390–401. doi:10.1038/sj.bjp.0707568. PMC 2219533. PMID 17994110.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)